Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

JHL Biotech Selects GE’s FlexFactory™ Biomanufacturing Platform for Taiwan Facility

Published: Tuesday, December 03, 2013
Last Updated: Tuesday, December 03, 2013
Bookmark and Share
GE Healthcare has completed installation of its FlexFactory™ biomanufacturing platform at JHL Biotech’s Research Center and manufacturing plant in Hsinchu, Taiwan.

The new manufacturing platform will follow current good manufacturing practices (cGMP) and be fully operational by the end of 2013.  It is similar to the production process at JHL Biotech’s KUBio modular biopharmaceutical factory currently under construction by GE Healthcare at the Biolake Science Park in Wuhan, China.

GE Healthcare’s FlexFactory is a centrally automated, flexible biomanufacturing platform.  It allows manufacturers to quickly and easily establish biopharmaceutical manufacturing capacity within an existing building or as part of a new facility.  Designed to help manufacturers such as JHL Biotech to rapidly respond to local healthcare needs and to support global customers in bringing lifesaving treatments to market more quickly, FlexFactory is comprised of single-use technologies and associated process hardware as well as all necessary automation and control components for start-to-finish manufacturing of biopharmaceuticals.

JHL Biotech’s FlexFactory in Taiwan will be used for cell line development, process development, and cGMP manufacturing in pre-clinical and early-stage clinical work.  In addition, it will serve as a “proving ground” for JHL Biotech for technology transfer.  GE Healthcare’s experienced Shanghai Fast Trak team will validate equipment at the site and will train local JHL Biotech staff.

JHL Biotech’s facility includes two 500L single-use bioreactors, with the option to expand to four if greater throughput is required.  FlexFactory enables JHL Biotech to develop manufacturing processes prior to launching full-scale manufacturing operations in its Taiwan facility and prior to its KUBio factory in Wuhan becoming fully operational in early 2015. 

Olivier Loeillot, General Manager of Enterprise Solutions, GE Healthcare Life Sciences, commented, “Our offering of tools, technologies and services for biomanufacturing has strength in both breadth and depth.  For JHL Biotech we have been able to take an approach which recognises the differing requirements of multiple sites, whilst at the same time allowing them to replicate processes.  FlexFactory is highly complementary to our KUBio offering, primarily aimed at those organisations repurposing or expanding an existing site.”

Racho Jordanov, Co-founder, President and CEO of JHL Biotech, added, “JHL Biotech will make world-class biopharmaceuticals affordable to more people by utilizing innovations such as FlexFactory.  Our biomanufacturing capability increases with the installation of cGMP manufacturing in our Taiwan facility.  Because our biomanufacturing capabilities are shared across our facilities in Asia, we give our partners a unique offering.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Expands European Capabilities
Expansion will see large volume sterile liquid handling capacity doubled.
Tuesday, April 12, 2016
GE Healthcare Life Sciences and Promosome Sign Licensing Agreement
Innovative mammalian cell line development technologies that show promise for increasing manufacturing efficiency of vital biopharmaceuticals.
Tuesday, April 29, 2014
GE Acquires Strategic Assets from Thermo
GE to acquire cell culture media and sera, gene modulation and magnetic beads businesses.
Monday, January 06, 2014
GE Healthcare’s 2012 Cell Imaging Competition - Voting Opens to Celebrate Art, Science and Discovery
Competition features both high-content analysis and high- and super-resolution microscopy cell images for the first time.
Thursday, November 22, 2012
Scientific News
Detecting Nano Amounts In Environmental Samples
The NanoUmwelt project is developing a technique that can detect nanomaterials in a variety of environmental samples.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Micro Heart Muscle Created from Stem Cells
Researchers have designed a new way to create micro heart muscle from stem cells using a unique dog bone dish.
“Secret Sauce” for Personalized, Functional Insulin-producing Cells
Researchers uncover molecular switch to make effective sugar-responsive, insulin-releasing cells in a dish, offering hope for diabetes therapy.
Insights into Early Human Embryo Development
Researchers at Karolinska Institutet and the Ludwig Cancer Research in Stockholm have conducted a detailed molecular analysis of the embryo’s first week of development.
Boosting Gene Transfer Capabilities
A new and highly efficient method for gene transfer has been developed.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
EU Project Aims to Cure Type 1 Diabetes
Researchers develop organoids from insulin-producing cells for transplantation.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!